logo-loader
viewAstraZeneca

AstraZeneca cancer drug fast-tracked by the FDA

AZ wants to offer Imfinzi to people with late-stage small cell lung cancer

AstraZeneca -

Anglo-Swedish drugs giant AstraZeneca PLC (LON:AZN) has been granted a priority review for a new drug’s use in a particularly aggressive and untreated form of lung cancer.

Imfinzi, which is already prescribed to treat bladder cancer, is being fast-tracked by the US Food & Drug Administration for deployment in patients with late-stage small cell lung cancer.

AZ hopes to have a product on the market early next year.

The application was supported by data from the phase III CASPIAN trial published in The Lancet, one of the world’s leading medical journals.

This showed Imfinzi in combination with the standard chemotherapy extended patients’ lives by a statistically significant three months.

Quick facts: AstraZeneca

Price: 7659 GBX

LSE:AZN
Market: LSE
Market Cap: £100.5 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Immotion plans fundraising following deal with Las Vegas resort

Immotion Group (LON:IMMO) has raised gross proceeds of £2.85mln from an 'oversubscribed' fundraising to accelerate its growth plans, and revealed it has inked a revenue-sharing deal with the MGM Mandalay Bay resort and casino in Las Vegas. CEO Martin Higginson tells Proactive London what the...

1 day, 15 hours ago

2 min read